{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T02:34:28Z","timestamp":1790476468256,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T00:00:00Z","timestamp":1601251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI109025"],"award-info":[{"award-number":["AI109025"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Rezafungin is a novel echinocandin drug being developed as a first-line option for treatment and prevention of invasive fungal infections. As a result of a structural modification in its parent molecule anidulafungin, rezafungin has acquired unique chemical stability conferring prolonged pharmacokinetics, as well as an administration advantage in the clinical setting compared to other drugs in the same class. Rezafungin displays potent in vitro activity against a wide spectrum of fungal pathogens, which is reflected in robust in vivo efficacy and\/or pharmacodynamic studies using various animal models as well as in promising clinical trials data. This review describes in vivo characterization of rezafungin using animal models, current status of clinical development and key findings from these studies.<\/jats:p>","DOI":"10.3390\/jof6040192","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T08:02:58Z","timestamp":1601280178000},"page":"192","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Review of the Novel Echinocandin Antifungal Rezafungin: Animal Studies and Clinical Data"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2664-2795","authenticated-orcid":false,"given":"Yanan","family":"Zhao","sequence":"first","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA"},{"name":"Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Perlin","sequence":"additional","affiliation":[{"name":"Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ 07110, USA"},{"name":"Department of Medical Sciences, Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.6.1.1","article-title":"Compounds active against cell walls of medically important fungi","volume":"6","author":"Hector","year":"1993","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/cid\/civ1194","article-title":"Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e00399-19","DOI":"10.1128\/AAC.00399-19","article-title":"Echinocandins for the Treatment of Invasive Aspergillosis: From Laboratory to Bedside","volume":"63","author":"Aruanno","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/ja.2016.89","article-title":"CD101, a novel echinocandin with exceptional stability properties and enhanced aqueous solubility","volume":"70","author":"Krishnan","year":"2017","journal-title":"J. Antibiot."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ong, V., James, K.D., Smith, S., and Krishnan, B.R. (2017). Pharmacokinetics of the Novel Echinocandin CD101 in Multiple Animal Species. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01626-16"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sandison, T., Ong, V., Lee, J., and Thye, D. (2017). Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01627-16"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"James, K.D., Laudeman, C.P., Malkar, N.B., Krishnan, R., and Polowy, K. (2017). Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin with Distinctive Pharmacokinetic Properties. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01541-16"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/cmi.12640","article-title":"CD101: A novel long-acting echinocandin","volume":"18","author":"Zhao","year":"2016","journal-title":"Cell. Microbiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e01009-17","DOI":"10.1128\/AAC.01009-17","article-title":"Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-abdominal Abscess Model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3396-3396","DOI":"10.1182\/blood.V128.22.3396.3396","article-title":"Efficacy of CD101, a Novel Echinocandin, in Prevention of Pneumocystis Pneumonia (PCP): Thwarting the Biphasic Life Cycle of Pneumocystis","volume":"128","author":"Cushion","year":"2016","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6872","DOI":"10.1128\/AAC.00701-16","article-title":"Preclinical Evaluation of the Stability, Safety, and Efficacy of CD101, a Novel Echinocandin","volume":"60","author":"Ong","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00546","DOI":"10.1002\/prp2.546","article-title":"Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK\/PD pharmacometrics of rezafungin efficacy","volume":"7","author":"Miesel","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e01165-19","DOI":"10.1128\/AAC.01165-19","article-title":"Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus","volume":"63","author":"Wiederhold","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Lepak, A.J., Zhao, M., and Andes, D.R. (2018). Pharmacodynamic Evaluation of Rezafungin (CD101) against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01572-18"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Lepak, A.J., Zhao, M., VanScoy, B., Ambrose, P.G., and Andes, D.R. (2018). Pharmacodynamics of a Long-Acting Echinocandin, CD101, in a Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.02154-17"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e01556-19","DOI":"10.1128\/AAC.01556-19","article-title":"Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model","volume":"63","author":"Lepak","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/jac\/dky153","article-title":"Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model","volume":"73","author":"Hager","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/j.bbmt.2019.12.353","article-title":"Rezafungin Prevention of Pneumocystis Pneumonia and Pneumocystis Reactivation Using Different Doses and Durations of Prophylaxis in a Mouse Model","volume":"26","author":"Ong","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","unstructured":"Long, L., Herrada, J., Caley, D., Munguba, G., Sherif, R., Bartizal, K., and Ghannoum, M.A. (2020, January 18\u201321). Evaluation of the efficacy of rezafungin in the treatment of Candida albicans endophthalmitis using a rabbit model. Proceedings of the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2020, Paris, France."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3201\/eid2301.161497","article-title":"Invasive Infections with Multidrug-Resistant Yeast Candida auris, Colombia","volume":"23","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mmy\/myy054","article-title":"Candida auris: The recent emergence of a multidrug-resistant fungal pathogen","volume":"57","author":"Forsberg","year":"2019","journal-title":"Med. Mycol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/ajt.14121","article-title":"Investigation of the First Seven Reported Cases of Candida auris, a Globally Emerging Invasive, Multidrug-Resistant Fungus-United States, May 2013\u2013August 2016","volume":"17","author":"Vallabhaneni","year":"2017","journal-title":"Am. J. Transplant."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Lakota, E.A., Bader, J.C., Ong, V., Bartizal, K., Miesel, L., Andes, D.R., Bhavnani, S.M., Rubino, C.M., Ambrose, P.G., and Lepak, A.J. (2017). Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00758-17"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.diagmicrobio.2017.10.021","article-title":"Activity of CD101, a long-acting echinocandin, against clinical isolates of Candida auris","volume":"90","author":"Berkow","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijantimicag.2017.03.028","article-title":"CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program","volume":"50","author":"Pfaller","year":"2017","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Pfaller, M.A., Messer, S.A., Rhomberg, P.R., and Castanheira, M. (2017). Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.02045-16"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cushion, M.T., Linke, M.J., Ashbaugh, A., Sesterhenn, T., Collins, M.S., Lynch, K., Brubaker, R., and Walzer, P.D. (2010). Echinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008524"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1093\/ofid\/ofy209.124","article-title":"1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and\/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study","volume":"5","author":"Thompson","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_31","unstructured":"Thompson, G.R., Honore, P.M., Horcajada, J.P., Fortun, J., Hites, M., Bassetti, M., Mena, K., Navalta, L., Viani, R., and Sandison, T. (2019, January 11\u201314). Rezafungin Clinical Safety and Efficacy in the Treatment of Candidaemia and\/or Invasive Candidiasis: Combined Results from the STRIVE Phase 2 Trial Parts A and B. Proceedings of the Trends in Medicial Mycology, Nice, France."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/LGT.0000000000000473","article-title":"CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial","volume":"23","author":"Nyirjesy","year":"2019","journal-title":"J. Low. Genit. Tract Dis."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/4\/192\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:14:22Z","timestamp":1760177662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/6\/4\/192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,28]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["jof6040192"],"URL":"https:\/\/doi.org\/10.3390\/jof6040192","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,28]]}}}